FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John “Chip” A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Inter.
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Geron Corporation ("Geron Corporation") (NASDAQ:GERN) concerning possible violations of federal securities laws. Geron announced its financial results for the fourth quarter and full year 2024 on February 26, 2025.
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Geron Corporation ("Geron Corporation") (NASDAQ:GERN) concerning possible violations of federal securities laws. Geron announced its financial results for the fourth quarter and full year 2024 on February 26, 2025.
NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ:GERN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Geron Corporation ("Geron Corporation") (NASDAQ:GERN) concerning possible violations of federal securities laws. Geron announced its financial results for the fourth quarter and full year 2024 on February 26, 2025.
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Geron Corporation ("Geron Corporation") (NASDAQ:GERN) concerning possible violations of federal securities laws. Geron announced its financial results for the fourth quarter and full year 2024 on February 26, 2025.
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ:GERN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Geron Corporation ("Geron Corporation") (NASDAQ:GERN) concerning possible violations of federal securities laws. Geron announced its financial results for the fourth quarter and full year 2024 on February 26, 2025.